Nano-X Imaging Future Growth
Future criteria checks 2/6
Nano-X Imaging is forecast to grow earnings and revenue by 63.7% and 43.6% per annum respectively while EPS is expected to grow by 64.5% per annum.
Key information
63.7%
Earnings growth rate
64.49%
EPS growth rate
| Healthcare earnings growth | 18.8% |
| Revenue growth rate | 43.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 22 Apr 2026 |
Recent future growth updates
Recent updates
NNOX: Reset Expectations And New Distribution Deals Could Support Upside
Analysts have trimmed their fair value estimate for Nano-X Imaging to $6.65 from $7.75 as they factor in updated assumptions around discount rates, long term revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent research has reset expectations around Nano-X Imaging, with analysts revisiting key inputs such as discount rates, long term revenue assumptions, margin potential, and future P/E levels.
NNOX: New Distribution Agreements Will Support Future Imaging Deployment Upside
Analysts have kept their $5.00 price target for Nano-X Imaging unchanged, citing only slight adjustments to long term revenue growth assumptions, profit margins and future P/E expectations that do not materially change their view of the stock's valuation. What's in the News Nanox Impact signed a new distribution agreement with Elite Surgical Technologies to deploy the FDA cleared Nanox.ARC tomosynthesis system across Ohio, Indiana, Michigan, Pittsburgh and West Virginia, with expectations for a minimum of five systems in year one and ten in year two, subject to market conditions and customer adoption (Key Developments).NNOX: New Global Imaging Deals And AI Platform Access Will Drive Upside
Analysts have adjusted their price target on Nano-X Imaging to $5.00. This keeps it in line with their fair value estimate as they update assumptions around revenue growth, profit margins and future P/E expectations.NNOX: New Distribution Deals And AI Partnerships Will Drive Future Upside
Analysts have modestly adjusted their Nano-X Imaging price targets, reflecting small recalibrations to long term revenue growth expectations, slightly higher projected profit margins, and a marginally lower future P/E assumption. What's in the News Nano-X Imaging announced that its US-based subsidiary, Nanox Impact Inc., signed a new distribution agreement with Imperial Imaging Technology LLC to support the commercial rollout of the Nanox.ARC multisource digital tomosynthesis system across several southeastern US states.NNOX: New Distribution Agreements And Software Rollout Will Support Future Upside Potential
Analysts have maintained their Nano-X Imaging fair value estimate at $5.00, citing only minor adjustments in projected revenue growth, profit margin, and future P/E assumptions instead of a significant change in their overall view. What's in the News Nano-X Imaging signed a distribution agreement with Intec SRL, which will act as the exclusive distributor for the Nanox.ARC system and related services in Argentina, covering marketing, distribution, installation, support, demonstrations, clinical evaluations, and training activities, with commercialization subject to required local regulatory approvals (Key Developments).NNOX: New Collaborations And Equity Raise Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Nano-X Imaging from US$7.00 to US$5.00, citing updated assumptions around discount rates, long term revenue growth, profit margins, and a lower future P/E multiple. What's in the News The FDA granted 510(k) clearance for TAP2D, a cloud enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X systems.NNOX: New Partnerships And Equity Raise Will Support Future Upside Potential
Analysts have modestly lifted their price target on Nano-X Imaging, citing an unchanged fair value at US$7.00, along with very large forecast revenue growth and slightly adjusted assumptions for the discount rate, profit margin and future P/E. What's in the News Nano-X Imaging filed and then completed a follow on equity offering of 3,826,530 ordinary shares, raising about US$15.0 million in a registered direct offering at US$3.92 per share, with a US$0.20 discount per share (Key Developments).NNOX: New Partnerships And EU Approval Will Support Future Upside Potential
Analysts have lifted their price target on Nano-X Imaging to US$7.00. The updated view reflects higher modeled revenue growth and a lower projected future P/E multiple, while fair value and discount rate assumptions remain essentially unchanged.NNOX: Expanding AI Imaging Partnerships Will Drive Future Global Deployment Upside
Analysts have nudged their price target on Nano-X Imaging slightly higher to reflect modest improvements in projected revenue growth, profit margins, and a marginally lower future price to earnings multiple. However, they have left their fair value estimate effectively unchanged at approximately 7.00 dollars per share.NNOX Will Benefit From Expanding AI Imaging Partnerships And Growing Global Deployments
Analysts have raised their price target on Nano-X Imaging by approximately 17 percent to reflect stronger projected revenue growth and modestly improved long term profitability, which is partially offset by a slightly higher discount rate and a lower assumed future price to earnings multiple. What's in the News Nano-X Imaging completed a registered direct follow on equity offering of approximately $15 million, issuing 3,826,530 ordinary shares at $3.92 per share to support growth initiatives (company filing).Nano-X Imaging (NASDAQ:NNOX) Has Debt But No Earnings; Should You Worry?
Oct 31
Digital Diagnostics And AI Will Open Global Markets
With both Net Profit Margin and Consensus Revenue Growth forecasts holding steady, analyst expectations for Nano-X Imaging remain unchanged, maintaining the price target at $7.75. What's in the News Nano-X Imaging announced a clinical and educational collaboration with Keiser University to deploy the Nanox.ARC imaging system at the Sarasota campus for training and demonstrations.Nano-X Imaging: Still No Opportunity Here
Aug 13Analysts Have Just Cut Their Nano-X Imaging Ltd. (NASDAQ:NNOX) Revenue Estimates By 39%
May 27
FDA And CE Mark Approvals Will Open European Imaging Markets
FDA clearance and European market entry through CE mark approval may significantly enhance Nano-X Imaging's revenue and market presence.Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Apr 01Nano-X Imaging: When Will The Hockey Stick Growth Happen?
Feb 14Nano-X Imaging's Recent Surge Is Undeserved
Jan 04We Think Some Shareholders May Hesitate To Increase Nano-X Imaging Ltd.'s (NASDAQ:NNOX) CEO Compensation
Dec 05Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Nov 25Nano-X Imaging: Bold Vision, Bearish Momentum, And High Investor Risk
Sep 29Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Apr 05Nano-X Imaging: System Deployments Finally Begin
Apr 01Nano-X Imaging gains on FDA submission for new digital X-ray technology
Sep 28Nano-X Imaging Q2 Earnings Preview
Aug 15Nano-X: Too Controversial To Buy
Jun 30Nano-X Imaging Q4 2021 Earnings Preview: Insight Coming Regarding This Binary Play
Mar 30Monday's Drop Isn't Likely The Last One For Nano-X
Dec 28Nano-X Imaging Stock Is A No-No Buy
Oct 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 110 | -11 | N/A | N/A | 3 |
| 12/31/2027 | 57 | -28 | N/A | N/A | 4 |
| 12/31/2026 | 32 | -47 | N/A | -31 | 4 |
| 12/31/2025 | 13 | -75 | -45 | -41 | N/A |
| 9/30/2025 | 12 | -56 | -45 | -41 | N/A |
| 6/30/2025 | 12 | -56 | -42 | -38 | N/A |
| 3/31/2025 | 12 | -55 | -41 | -37 | N/A |
| 12/31/2024 | 11 | -54 | -39 | -37 | N/A |
| 9/30/2024 | 11 | -50 | -41 | -39 | N/A |
| 6/30/2024 | 10 | -57 | -44 | -42 | N/A |
| 3/31/2024 | 10 | -61 | -45 | -44 | N/A |
| 12/31/2023 | 10 | -61 | -48 | -45 | N/A |
| 9/30/2023 | 10 | -103 | -49 | -47 | N/A |
| 6/30/2023 | 10 | -101 | -45 | -42 | N/A |
| 3/31/2023 | 9 | -103 | -48 | -43 | N/A |
| 12/31/2022 | 9 | -113 | -51 | -43 | N/A |
| 9/30/2022 | 8 | -82 | -63 | -50 | N/A |
| 6/30/2022 | 5 | -77 | -65 | -49 | N/A |
| 3/31/2022 | 3 | -71 | -66 | -45 | N/A |
| 12/31/2021 | 1 | -62 | -61 | -38 | N/A |
| 9/30/2021 | N/A | -59 | N/A | N/A | N/A |
| 6/30/2021 | N/A | -56 | N/A | N/A | N/A |
| 3/31/2021 | N/A | -49 | N/A | N/A | N/A |
| 12/31/2020 | N/A | -44 | -36 | -22 | N/A |
| 9/30/2020 | N/A | -44 | -13 | -12 | N/A |
| 6/30/2020 | N/A | -35 | -9 | -9 | N/A |
| 3/31/2020 | N/A | -29 | N/A | N/A | N/A |
| 12/31/2019 | N/A | -23 | -6 | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NNOX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NNOX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NNOX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NNOX's revenue (43.6% per year) is forecast to grow faster than the US market (11.1% per year).
High Growth Revenue: NNOX's revenue (43.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NNOX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/29 06:59 |
| End of Day Share Price | 2026/04/29 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nano-X Imaging Ltd. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| Scott Henry | Alliance Global Partners |
| Ravi Misra | Berenberg |